Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 May 22:11:190.
doi: 10.1186/1471-2407-11-190.

Treatment of malignant sinonasal tumours with intensity-modulated radiotherapy (IMRT) and carbon ion boost (C12)

Alexandra D Jensen  1 , Anna V Nikoghosyan, Christine Windemuth-Kieselbach, Jürgen Debus, Marc W Münter
Affiliations
Clinical Trial

Treatment of malignant sinonasal tumours with intensity-modulated radiotherapy (IMRT) and carbon ion boost (C12)

Alexandra D Jensen et al. BMC Cancer. .

Abstract

Background: Most patients with cancers of the nasal cavity or paranasal sinuses are candidates of radiation therapy either due incomplete resection or technical inoperability. Local control in this disease is dose dependent but technically challenging due to close proximity of critical organs and accompanying toxicity. Modern techniques such as IMRT improve toxicity rates while local control remains unchanged. Raster-scanned carbon ion therapy with highly conformal dose distributions may allow higher doses at comparable or reduced side-effects.

Methods/design: The IMRT-HIT-SNT trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°III) and efficacy (secondary endpoint: local control, disease-free and overall survival) in the combined treatment with IMRT and carbon ion boost in 30 patients with histologically proven (≥R1-resected or inoperable) adeno-/or squamous cell carcinoma of the nasal cavity or paransal sinuses. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (50 Gy at 2.0 Gy/fraction).

Discussion: The primary objective of IMRT-HIT-SNT is to evaluate toxicity and feasibility of the proposed treatment in sinonasal malignancies.

Trial registration: Clinical trial identifier NCT 01220752.

Trial registration: ClinicalTrials.gov NCT01220752.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial flow chart.
Figure 2
Figure 2
Follow-up.
See this image and copyright information in PMC

References

    1. Muir CS, Nectoux J. Descritptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses. Clin Otolaryngol Allied Sci. 1980;5:195–211. doi: 10.1111/j.1365-2273.1980.tb01647.x. - DOI - PubMed
    1. Rousch G. Epidemiology of cancer of nose and paranasal sinus carcinomas: current concepts. Head Neck Surg. 1979;2:3–11. doi: 10.1002/hed.2890020103. - DOI - PubMed
    1. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys. 2009;73:424–432. doi: 10.1016/j.ijrobp.2008.04.037. - DOI - PubMed
    1. Licitra L, Locati LD, Cavina R, Garassino I, Mattavelli F, Pizzi N. et al.Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol. 2003;14:367–372. doi: 10.1093/annonc/mdg113. - DOI - PubMed
    1. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001;92:3012–3029. doi: 10.1002/1097-0142(20011215)92:12<3012::AID-CNCR10131>3.0.CO;2-E. - DOI - PubMed

Publication types

Substances

Associated data